亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.

作者
Dongsheng Yue,Shidong Xu,Qun Wang,Xiaofei Li,Yi Shen,Heng Zhao,Chun Chen,Weimin Mao,Wei Liu,Junfeng Liu,Lanjun Zhang,Haitao Ma,Qiang Li,Yue Yang,Yongyu Liu,Haiquan Chen,Zhenfa Zhang,Bin Zhang,Fuyu Gong,Changli Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 8520-8520 被引量:9
标识
DOI:10.1200/jco.2021.39.15_suppl.8520
摘要

8520 Background: The EVAN study of E vs NP in stage III EGFR+ NSCLC has met its primary endpoint and been previously published: 2-year disease-free survival was 81.4% (95% CI, 69.6–93.1) in E group vs 44.6% (95% CI, 26.9-62.4) in NP group (HR, 1.823; 95% CI, 1.194–2.784; P=0.0054). We report 5-year OS and exploratory results from EVAN with a further 43 month follow up (cutoff date: Jan 6, 2021). Methods: Patients with stage IIIA EGFR+ NSCLC were randomized assigned (1:1) into either E arm (n=51, 150mg/day) or NP arm (n=51, vinorelbine 25mg/m2 on day 1, 8 and cisplatin 75mg/m2 on day 1 of a 21-day cycle). In order to explore the relationship between patient benefits and co-occurring variants, 47 patients received whole exome sequencing (WES) analysis (E, n=24; NP, n=23). Results: Median follow-up time was 54.8 months for E and 63.9 months for NP. E improved OS and 5-year survival rate compared with NP in ITT population. The median OS was 84.2m (95% CI, 78.1,-) with E vs 61.1m (95% CI, 39.6-82.1) with NP (HR, 0.318; 95% CI, 0.151-0.670). The 5-year survival rates were 84.8% (95%CI, 72.0-97.6) and 51.1% (95% CI, 34.7-67.5), respectively. In the WES analysis, we found that the most frequent genes with co-occurring variants at baseline were TP53, MUC16, FAM104B, KMT5A and DNAH9, and additional EGFR variants, each with similar prevalence regardless of EGFR-activating mutation subgroup. Moreover, in the erlotinib-treated patients, the SNP mutation of UBXN11 was associated with significantly worse DFS (P=0.0111). Conclusions: This is the first randomized study of EGFR-TKI to demonstrate a clinically meaningful improvement in OS vs chemotherapy in stage III EGFR+ NSCLC (5-year survival rate 84.8% in E vs 51.1% in NP). The co-occurring variants at baseline may be associated with reduced DFS. Further studies are required to confirm our results (EVAN, NCT01683175). Clinical trial information: NCT01683175.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qfhbg完成签到,获得积分10
1秒前
落后哈密瓜完成签到,获得积分10
2秒前
wetg完成签到,获得积分10
5秒前
学霸业的应助被369ninja采纳,获得10
6秒前
portik完成签到,获得积分10
10秒前
要减肥的菀完成签到,获得积分10
11秒前
hgjk完成签到,获得积分10
15秒前
18秒前
sdf完成签到,获得积分10
20秒前
VDC的应助被369ninja采纳,获得30
23秒前
amz完成签到,获得积分10
24秒前
adefgv完成签到,获得积分10
29秒前
科目三的应助被科研通管家采纳,获得10
32秒前
fhjg完成签到,获得积分10
34秒前
Nole的应助被369ninja采纳,获得10
38秒前
jtk完成签到,获得积分10
39秒前
pwn完成签到,获得积分10
43秒前
45秒前
虚心的手套完成签到,获得积分10
48秒前
wh完成签到,获得积分10
49秒前
369ninja发布了新的文献求助10
50秒前
50秒前
我是笨蛋完成签到 ,获得积分10
52秒前
CodeCraft的应助被369ninja采纳,获得10
53秒前
fsw完成签到,获得积分10
53秒前
sd完成签到,获得积分10
58秒前
安静白柏完成签到,获得积分10
1分钟前
li1完成签到,获得积分10
1分钟前
充电宝的应助被369ninja采纳,获得10
1分钟前
EK1完成签到,获得积分10
1分钟前
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
fr1完成签到,获得积分10
1分钟前
Jasper的应助被369ninja采纳,获得10
1分钟前
1分钟前
FR完成签到,获得积分10
1分钟前
舒心谷菱完成签到,获得积分10
1分钟前
1分钟前
ly完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808464
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557361
邀请新用户注册赠送积分活动 2478958